Galapagos is a clinical stage biotech company focused on developing novel mode of action medicines.  Headquartered in Belgium, the Company employs 400 people and reported 2013 revenues of €160 million. 

Galapagos’ most advanced candidate drug filgotinib shows excellent safety and efficacy in rheumatoid arthritis patients and is fully proprietary to Galapagos. With filgotinib, Galapagos demonstrates its capabilities in developing novel medicines for difficult to cure diseases.

  • Click here for the DARWIN Phase 2b trial design for filgotinib
  • Click here for the DDI poster on filgotinib at ACR 2014
  • Click here for the modelling poster on filgotinib at ACR 2014
  • Click here for the gene signature poster on filgotinib at ACR 2014
  • Click here for the UEGW 2014 presentation on GPR84
  • Click here for the UEGW 2014 poster on GLPG1205
  • Click here for the NACFC 2014 poster on novel CF correctors
  • Click here for the ECFC 2014 presentation on our CF programs

 

 
 
 
 

© Copyright 2015 Galapagos NV | Disclaimer General Purchase Terms  

 
Test